← ANALYST RATINGS · TIPRANKS
Sutro Biopharma (STRO): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $52.20, the highest $60.00, the lowest $48.00. The average is +377.1% from the last price of $10.94.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $50.00 | Buy | +357.0% | Reiterated | 16.10.26on TipRanks 06:35 | −3.4% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $60.00 | Buy | +448.4% | Reiterated | 15.10.26on TipRanks Oct 16 03:25 | +8.7%next day −3.4% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $10.00−9.1% | Hold | −8.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $10.00−4.8% | Hold | −8.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $10.00−4.8% | Hold | −8.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.00 → $10.00−9.1% | Hold | −8.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $10.00−4.8% | Hold | −8.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 → $10.50−19.2% | Hold | −4.0% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Lukas Shumway★★★★★★★★★★#6090 · hits 67% · avg +8.8% | Barclays | $56.00 | Buy | +411.9% | Reiterated | 01.10.26on TipRanks 05:15 | −1.0%next day −4.6% · 5 days −5.4% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $49.00 | Buy | +347.9% | Reiterated | 29.09.26on TipRanks Sep 30 05:25 | +0.6%next day +0.3% · 5 days −12.2% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $48.00 | Buy | +338.8% | Reiterated | 17.08.26on TipRanks 07:20 | +9.3%next day −0.4% · 5 days −6.8% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Sell | — | Reiterated | 14.08.26on TipRanks 11:15 | −3.7%next day +9.3% · 5 days +4.1% | ↗ |
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | $50.00 | Buy | +357.0% | Reiterated | 13.08.26on TipRanks 07:50 | −0.6%next day −3.7% · 5 days +1.3% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Reiterated | 12.08.26on TipRanks Aug 13 10:25 | −15.2%next day −0.6% · 5 days +3.3% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $54.00 | Buy | +393.6% | Reiterated | 12.08.26on TipRanks 09:35 | −15.2%next day −0.6% · 5 days +3.3% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $38.00 → $43.00+13.2% | Buy | +293.1% | Assigned | 15.05.26on TipRanks 06:15 | +2.6%next day −11.5% · 5 days −35.3% | ↗ |
| Joseph Catanzaro★★★★★★★★★★#981 · hits 46% · avg +13.3% | Mizuho Securities | $50.00 | Buy | +357.0% | Initiated | 30.04.26on TipRanks 05:20 | +2.5%next day −3.1% · 5 days +7.0% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $35.00 → $41.00+17.1% | Buy | +274.8% | Reiterated | 23.04.26on TipRanks 05:45 | −1.6%next day −5.1% · 5 days +3.7% | ↗ |
| James Shin★★★★★★★★★★#4468 · hits 57% · avg +7.3% | Deutsche Bank | $51.00 → $55.00+7.8% | Buy | +402.7% | Reiterated | 25.03.26on TipRanks 08:55 | −0.9%next day +7.8% · 5 days +6.1% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $20.00 | Buy | +82.8% | Reiterated | 04.12.25on TipRanks 07:45 | +7.7%next day −7.9% · 5 days +3.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sutro Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $51.17 at a price of $16.11 (+217.6%); now: $52.43 at $10.94 (+379.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 7 | 9 |
| Buy | 10 | 7 | 4 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.66 (from $-2.86 to $0.76). Last quarter: $-2.33.
Sales
Next quarter’s sales estimate — $14M (from $2M to $50M). Last quarter: $10M.
Best top-analyst consensus in the sector · Healthcare
About Sutro Biopharma
- CEO: Jane Chung
- Employees: 128
- 111 Oyster Point Boulevard, South San Francisco, CA, 94080, US
- www.sutrobio.com
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 62 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗